About two and a half years before they sealed a $3.3 billion deal, Bain Capital and its life sciences team started courting ...
Through this platform, Carlyle will help Roop and Highway leverage operating synergies, create capabilities and capacities ...
We recently published a list of 11 AI News and Ratings on Investors’ Radar. In this article, we are going to take a look at ...
We recently published a list of 11 AI News and Ratings on Investors’ Radar. In this article, we are going to take a look at ...
U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...
Hosted on MSN1d
Keybanc Initiates Coverage of Rapid Micro Biosystems (RPID) with Overweight RecommendationFintel reports that on February 12, 2025, Keybanc initiated coverage of Rapid Micro Biosystems (NasdaqCM:RPID) with a ...
Massachusetts, USA-based cell therapy specialist Abcuro today announced the closing of a $200 million Series C financing.
Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors.
Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle ...
Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the ...
LightBay Capital has made a strategic growth investment in Ro Health, according to a news release. Ro Health, founded in 2013 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback